Please login to the form below

Not currently logged in
Email:
Password:

Bitter pill awards for pharma firms

Health advocacy group highlights 'questionable' prescription drug marketing practices

Five pharma firms in the US have been singled out for 'over-zealous and questionable marketing practices' by health and consumer advocacy group, the Prescription Access Litigation Project (PAL).

PAL gave 'bitter pill' awards to Sepracor for sleeping disorder drug, Lunesta, sanofi-aventis for sleeping pill, Ambien, Eli Lilly for attention deficit hyperactivity disorder drug, Strattera, and AstraZeneca for cholesterol-lowering drug, Crestor.

The awards were created in 2005 to highlight the potential problems of excessive prescription drug marketing, particularly direct-to-consumer advertising, the group said.

ìA lot of money is riding on drug companies convincing consumers that they have insomnia, acid reflux, high cholesterol, allergies, depression, toenail fungus and erectile dysfunction, and that they need to have expensive brand-name drugs to treat them,î said PAL director, Alex Sugarman-Brozan.

PAL also gave an award to US pharmaceutical trade organisation, the Pharmaceutical Research and Manufacturers of America (PhRMA), for not enforcing the direct-to-consumer advertising guidelines it issued last year.

In a statement, PhRMA responded that the guidelines ìare beginning to work, and we believe they should be given additional time to function more robustlyî.

2nd September 2008

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

4 ways to recruit Alzheimer’s disease patients for your clinical trial
What key things do you need to remember to reach patients living with Alzheimer’s disease?...
competitive intelligence
Integrating competitive intelligence into business development, licensing and M&A strategy
The advantages of partnering with a competitive intelligence or knowledge management team...
reaching HCPs during pandemic
Reaching patients and HCPs during the pandemic
COVID-19 has caused unprecedented disruption to drug launches, but some pharma companies avoided costly delays by quickly pivoting to digital channels...

Infographics